Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
The DOI matches its Crossref record.
Abstract
2535 Background: RG7388 is an oral pyrrolidine designed as a potent antagonist of MDM2. Preclinical studies demonstrate p53 activation, tumor growth inhibition, & increased life span in xenograft models. Methods: A phase 1 study in solid tumor pts was conducted to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), food-effect (FE) & biomarker (BM) activity of RG7388. Administration schedules of once weekly (qwk) x 3, & daily (3 or 5d) every 28d were evaluated. Following initial accelerated titration, a modified continual reassessment method-escalation with overdose control (EWOC) requiring at least 2 DLT evaluable pts per cohort, was used to guide escalation. Enrolment in BM cohorts was initiated at the prior dose level once EWOC was triggered. PK, baseline p53 & MDM2 status, & serum MIC-1 (a marker for p53 activation) were measured for all pts. The FE cohort consisted of 10 pts in a randomized, 3-way crossover, partial-replicate design. In BM cohorts, tumor biopsies were collected pre-dose & during cycle 1 for analysis of p53 activation, anti-proliferative & pro-apoptotic effects of RG7388. Correlative changes in FLT-PET imaging were also assessed. Results: Accrual to dose escalation, FE & core BM cohorts is complete: 46 pts enrolled on the qwk schedule (7 dose levels from 100 - 3200 mg qwk x 3); 49 pts enrolled on the daily schedule: 34 pts treated for 5d at 8 dose levels (100 - 1200 mg daily) & 15 pts treated for 3d at 2 dose levels (1000 & 1600 mg daily). Nausea/vomiting & myelosuppression (more frequent in the daily dosing schedule & associated with PK exposure) were the DLTs. MTD per schedule was: 1600 mg bid qwk x 3; 500 mg bid x 3d & 500 mg qd x 5d. Dose-PK exposure was proportional up to 2,400 mg/d; t½: ~ 1 d. No major effect of high-fat food on PK exposure was seen. MIC-1 activation was seen at the lowest dose evaluated. Preliminary BM results suggest that p53 activation is greater with 5d dosing than with other schedules at respective MTDs. Stable disease for 17, 22 & 23+ months has been seen in sarcoma pts. Conclusions: RG7388 demonstrates p53 activation which may be dose & schedule dependent and warrants further evaluation. Safety, PK, FE, PD & BM results will be presented. Clinical trial information: NCT01462175.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Self-citationTargeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
“3), the first MDM2 inhibitor to be advanced into human clinical trials (Vu et al. 2013; Siu et al. 2014).”
BackgroundZhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
“Inhibition of MDM2 alone cannot completely release and activate p53 protein [25, 105], which can induce the overexpression of MDMX, thereby reducing the effect of MDM2 inhibitors and promoting drug resistance [106].”
BackgroundSaleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0715 · Cited by 159
Metadata
- Authors
- Siu, L. L., Italiano, A., Miller, W. H., Blay, J.-Y., Gietema, J. A., Bang, Y.-J., Mileshkin, L. R., Hirte, H. W., Reckner, M., Higgins, B., Jukofsky, L., Blotner, S., Zhi, J., Middleton, S., Nichols, G. L., & Chen, L. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-20
- Volume
- 32
- Issue
- 15_suppl
- Pages
- 2535-2535
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2508895628
- Cited by
- 60
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.2535
- The paper
- Siu, L. L., Italiano, A., Miller, W. H., Blay, J.-Y., Gietema, J. A., Bang, Y.-J., Mileshkin, L. R., Hirte, H. W., Reckner, M., Higgins, B., Jukofsky, L., Blotner, S., Zhi, J., Middleton, S., Nichols, G. L., & Chen, L. C. (2014). Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.2535
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.